DNA microchips (microarrays) in follicular lymphoma diagnostics: the pathway to „tailor-made“ therapy or to impasse?
Authors:
A. Janíková 1; K. Staňo-Kozubík 2; B. Tichý 2; J. Mayer 1; Z. Král 1; J. Michalka 1; I. Vášová 1; Š. Pospíšilová 2
Authors‘ workplace:
Interní hematoonkologická klinika FN Brno Bohunice a LF Masarykovy univerzity Brno
1; Centrum molekulární biologie a genové terapie Interní hematoonkologické kliniky FN Brno Bohunice
a LF Masarykovy univerzity Brno
2
Published in:
Transfuze Hematol. dnes,14, 2008, No. 4, p. 188-194.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Follicular lymphoma (FL), an indolent B-lymphoproliferative disorder, is characterized by a long median survival of 8 to 10 years. Transformation to more aggressive lymphoma with poor prognosis occurs in 25–60% of patients with FL. Up to now; FL is considered to be an incurable disease with unpredictable individual course. Translocation t(14;18), the traditional genetic hallmark of FL, is of limited clinical importance only. Prognostic and laboratory parameters actually used have not been successful in individual stratification of FL patients as well. DNA microarrays enables analyses of the genomic expression program providing new insights into molecular pathogenesis of tumours. Gene expression profiling can reveal morphologically indistinguishable subgroups with different clinical behaviour in the frame of single disease, new important genes or prognosis based on molecular features. In principle, DNA microarrays are based on hybridization of tested nucleic acids (in expression microarrays RNA) with complementary oligonucleotide probes immobilized on the matrix of microarrays. The quantity of data generated by these techniques (usually thousands to tens of thousands genes) requires statistical analysis. There are several studies analysing gene expression profiling in FL from various aspects, published results generally indicate, that expression profiling of FL is relatively homogenous, transformed FL is clonally identical with its original indolent counterpart and its expression signature is more similar to those observed in FL than to those observed in de novo DLBCL. Transformation is heterogeneous process proceeded probably by at least two pathways. The nature of infiltrating non-B-cells of microenvironment seems to be of a great importance, concerning behaviour and prognosis of FL.
Key words:
follicular lymphoma, diagnosis, prognosis, gene expression profiling, DNA microarrays
Sources
1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of hemopoietic and lymphoid tissues: report of the Clinical Advisory Comittee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–49.
2. Lossos I., Levy R. Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Seminars in Cancer Biology 2003; 13: 191–202.
3. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993; 20 (suppl 5): 75–88.
4. The Non-Hodgkin’s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group of non-Hodgkin’s lymphoma. Blood 1997; 89: 3909–3918.
5. Nathwani BN, Harris NL, Weisenburger D. Follicular lymphoma. In: Pathology an genetics of tumours of haematopoietic and lymphoid tissues. Jaffe ES, Harris NL, Stein H et al (eds.) Lyon, France, IARC Press 2001; 162–167.
6. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predective model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783–789.
7. Solal-Céligny P, Roy P. Follicular lymphoma International Prognostic Index (FLIPI). Blood 2004; 104: 1258–65.
8. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients – a study of the groupe d’Étude des lymphomes de l’Adulte. J Clin Oncol 1999; 17: 2499–2505.
9. Radojkovic M, Ristic S, Colovic M, Mihaljevic B, Cemerikic-Martinovic V. Predictive Value of Prognostic Indices in Patients with Follicular Lymphomas. Med Oncol 2006; 23: 533–42.
10. Vose JM, Bierman PJ, Loberiza FR, et al. Long-term outcomes of autologous stem cell transplantation for follicular Non-Hodgkin’s Lymphomas: Effect of histological grade and Follicular Lymphoma International Prognostic Index. Biol Blood Marrow Transplant 2008; 14: 36–42.
11. Limpens J, de Jong D, van Krieken JH, et al. Bcl-2/JH rearragements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271–2276.
12. Obořilová A, Dvořáková D, Mayer J. Translokace t(14;18) a její význam ve sledování minimální zbytkové nemoci u folikulárního lymfomu. Transfuze a hematologie dnes 2004; 10: 51–61.
13. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
14. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.
15. Robetorye RS, Bohling S, Morgan JW, Fillmore GC, Lim MS, Elenitoba-Johnson KS. Microarray analysis of B-cell lymphoma cell lines with t(14;18). Journal of Molecular Diagnostics 2002; 4: 123–136.
16. Maesako Y, Uchiyama T and Ohno H. Comparison of gene expression profiles of lymphoma cell lines from follicular lymphoma, Burkitt’s lymphoma and de novo DLBCL. Cancer Sci 2003; 94: 774–781.
17. Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with heterogenous set of DNA copy number and gene expression alterations. Blood 2003; 101: 3109–3117.
18. Schmechel SC, LeVasseur RJ, Yang KHJ, Koehler KM, Kussick SJ, Sabath DE. Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma. Leukemia 2004; 18: 841–855.
19. Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99: 282–289.
20. Fujii A, Oshima K, Hamasaki M, et al. Differential expression of cytokines, chemokines, and their receptors in follicular lymphoma and reactive follicular hyperplasia: Assessment by complementary DNA microarray. Oncology Reports 2005; 13: 819–824.
21. Tarte K, Pangault C, de Vos J, et al. Gene expression profiling of highly purified malignant and non-malignant cells: characterization of the tumor-microenvironment cellular synapse in de novo follicular lymphoma (FL). Blood 2007; 110: 111a (abstr No 355).
22. Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Blood 2007; 136: 286–293.
23. de Vos S, Hofmann WF, Grogan TM, et al. Gene expression profile of serial samples of transformed B-cell Lymphomas. Lab Invest 2003; 83: 271–285.
24. Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. PNAS 2002; 99: 8886–8891.
25. Elenitoba-Johnson KSJ, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathway in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. PNAS 2003; 100: 7259–7264.
26. Glas AM, Kersten MJ, Delahaye LJMJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301–307.
27. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25: 390–398.
28. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–69.
29. Johnson NA, Nayar T, Dave SS, et al. Gene expression model of survival and transformation in follicular lymphoma (FL) a study by the LLMPP. Blood 2007; 118: 767a (abstr No 2606).
30. Byers RJ, Sakhinia E, Preethi J, et al. Clinical measurement of prognostic immune signature in follicular lymphoma by RT-PCR based gene expression profiling and immunohistochemistry demonstrates favourable T-cell and unfavourable macrophage infiltration. Blood 2007; 110: 112a (abstr No 359).
31. Farinha P, Al-Tourah A, Connors JM, Gascoyne RD. The architectural pattern of POXP3+ T-cells predicts risk of transformation in patients with follicular lymphoma (FL). Blood 2007; 110: 112a (abstr 358).
32. Bohen SP, Troyanskaya OG, Alter O, et al. Variation of gene expression patterns in follicular lymphoma and the response to rituximab. PNAS 2003; 100: 1926–1930.
33. Björck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favourable outcome in patients with follicular lymphoma. Blood 2005; 105: 2908–2915.
34. Harjunpää A, Taskinen M, Nykter M, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. BJH 2006; 135: 33–42.
35. Irish JM, Hsu FY, Sharman JP, et al. A profile of 648 signaling network events identifies cell subsets with diverse, abnormal responses to lymphocyte stimuli within follicular lymphoma tumors. lood 2007; 110: 111a (abstr No 356).
36. Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2007; 110: 113a (abstr No 360).
37. Lossos IS, Morgensztern D. Non-Hodgkin’s lymphoma in the microarray era. Clinical Lymphoma 2004; 128–129.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2008 Issue 4
Most read in this issue
- MicroRNA – small molecules with major role (not only) in hematological malignancies
- Imatinib in the first-line treatment of chronic myelogenous leukemia in chronic phase
- Apheresis red cell concentrates - evaluation of apoptosis markers in concentrates obtained from two devices
- Second national study AML-BFM 98 improved remission rate and overall survival in children with acute myeloid leukemia in the Czech Republic